Hong Kong Stock MovementREMEGEN rose 10.04%. Based on recent key news:<ol><li>On January 5, data from the National Medical Products Administration showed that the total amount of innovative drug licensing transactions in China is expected to exceed USD 130 billion by 2025, a year-on-year increase of over 150%. This trend indicates the rapid development of the innovative drug industry, driving up the stock prices of related companies like REMEGEN.</li><li>On January 5, Zhitong Finance reported that REMEGEN has not yet started its share repurchase but plans to implement it opportunistically within the repurchase period. This news may enhance market confidence in the company's future stock performance, boosting its stock price.</li><li>On January 5, the Hong Kong innovative drug ETF surged, and REMEGEN, as one of the component stocks, benefited from the overall positive market sentiment, leading to a rise in its stock price. The innovative drug industry has entered a rapid development phase, with significant capital inflows.</li></ol>Stocks with High Trading Volume in the IndustryInnovent Biologics rose 4.20%. Based on recent key news:<ol><li>On January 5, Innovent Biologics performed strongly in the Hong Kong stock market, with its stock price rising by 6%. This was mainly due to capital inflows after the mainland stock market reopened, particularly a net purchase of RMB 18.7 billion from northbound funds, boosting pharmaceutical-related stocks. As a leader in the pharmaceutical sector, Innovent Biologics benefited from market capital favor, leading to a significant rise in its stock price. Source: Zhitong Finance</li><li>On January 6, Innovent Biologics' GLP-1 weight loss drug, Ma Shidu, stood out in market competition. Nomura Securities analysts pointed out that despite increasing market competition, Innovent Biologics is expected to benefit from its high pricing point and differentiated mechanism, supporting its future growth due to the first-mover advantage in scaled sales. Source: Nomura Securities</li><li>On January 6, Innovent Biologics' innovative drug products were once again included in the medical insurance catalog, further consolidating its market position. The company's product layout in multiple fields, including metabolism, autoimmune, and ophthalmology, demonstrates strong market potential, driving up its stock price. Source: Market Value Observation Pharmaceutical sector capital inflows are significant, risks need attention.</li></ol>Akeso, Inc. rose 5.48%. Based on recent key news:<ol><li>On January 6, Akeso's PD-1/VEGF bispecific antibody, Ivosidenib, received approval from the National Medical Products Administration of China for label modification. This update marks a significant milestone for the company and its products in the Chinese market, driving up its stock price. Source: Akeso, Inc.</li><li>On January 7, Ivosidenib was included in the National Medical Insurance Drug Catalog of China, expanding patient accessibility. This move supports Ivosidenib's sales in the Chinese market, further boosting its stock price. Source: Akeso, Inc.</li><li>On January 5, Daiwa published a report stating that Akeso lacks short-term catalysts, downgrading its rating from &#34;Buy&#34; to &#34;Hold.&#34; Nevertheless, the global sales forecast for Ivosidenib has been raised, with the target price increased from HKD 100 to HKD 116, and the market remains optimistic about its long-term prospects. Source: Daiwa Securities The biopharmaceutical industry has recently performed strongly, with significant capital inflowsBeiGene rose by 1.92%. Based on recent key news:</li><li>On January 6, BeiGene announced that its new drug Sotigalimab received conditional approval from the National Medical Products Administration for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma patients. This approval brings new market opportunities for the company, driving up its stock price. Source: Jinshi Data</li><li>On January 5, the Hang Seng Pharmaceutical ETF surged by 5.1%, reflecting market optimism towards the innovative drug sector. BeiGene, as one of the representative companies, benefited from this trend. Source: Daily Economic News</li><li>On January 6, competition in the domestic BCL-2 inhibitor market intensified, with BeiGene's Sotigalimab seen as the next blockbuster product, and the market is full of expectations for its future performance. Source: Times Weekly. The innovative drug sector is supported by policies, and the market is optimistic.</li></ol>Stocks ranked among the top in industry market capitalizationKanglongda Biotech-B rose by 4.31%. Based on recent news,<ol><li>On January 5, the Hong Kong stock pharmaceutical sector was collectively active, with Kanglongda Biotech-B rising by 7.79%. The number of innovative drug approvals and the amount of external licensing transactions released by the National Medical Products Administration reached a historical high, boosting market sentiment.</li><li>On January 5, Kanglongda Biotech-B's core product, Lukanumab combined with Pembrolizumab for first-line treatment of non-small cell lung cancer, received breakthrough therapy designation from the National Medical Products Administration of China, significantly enhancing market confidence in the company's future development.</li><li>On January 5, the company's self-developed targeted integrin β6 antibody-drug conjugate SKB105's new drug clinical trial application was approved for the treatment of advanced solid tumors, further strengthening the company's competitiveness in the innovative drug field. The pharmaceutical industry has entered a critical stage of innovation realization and global layout</li></ol>

09995

01801

09926

06160

06990

REMEGEN rose 10.04%; Innovent Biologics rose 4.20%, with a transaction volume reaching HKD 1.214 billion; CanSino Biologics rose 5.48%, with a transaction volume reaching HKD 1.058 billion; BeiGene rose 1.92%, with a transaction volume reaching HKD 844 million; Kelun-Biotech rose 4.31%, with a market value reaching HKD 107.3 billion

HK Stock Movers Tracker

REMEGEN

INNOVENT BIO

AKESO

BEONE MEDICINES

SKB BIO-B

Hong Kong stock movement: The innovative drug industry explodes, REMEGEN rises 10.04%